Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 3/20 | 0.56 |
| ▸ | KCNQ2 | O43526 | 3/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.56 |
| ▸ | ESR1 | P03372 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | CASP1 | P29466 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15004064 | 0.79 | KCNQ3 (0.65) | KCNQ3KCNQ2HSD17B10ABCB11ESR1 | |
| SCHEMBL16616629 | 0.78 | KCNQ2 (0.57) | KCNQ3KCNQ2HSD17B10ABCB11ESR1 | |
| SCHEMBL21623741 | 0.77 | PKM (0.39) | CYP1A2MAPK1CYP2C19ALDH1A1MAPT | |
| SCHEMBL12505604 | 0.75 | KCNQ3 (0.74) | KCNQ3KCNQ2HSD17B10ABCB11ESR1 | |
| SCHEMBL7799378 | 0.75 | MAPK1 (0.49) | KCNQ3KCNQ2HSD17B10ABCB11ESR1 | |
| SCHEMBL16616466 | 0.74 | KCNQ2 (0.46) | KCNQ3KCNQ2HSD17B10ABCB11ESR1 | |
| SCHEMBL4890687 | 0.74 | KCNQ3 (0.72) | KCNQ3KCNQ2HSD17B10ABCB11ESR1 | |
| SCHEMBL16616598 | 0.74 | KCNQ3 (0.45) | KCNQ3KCNQ2HSD17B10ABCB11ESR1 | |
| Hydrochloric Acid SCHEMBL10786035 | 0.73 | KCNQ3 (0.71) | KCNQ3KCNQ2HSD17B10ABCB11ESR1 | |
| Hydrochloric Acid SCHEMBL31741641 | 0.73 | KCNQ3 (0.71) | KCNQ3KCNQ2HSD17B10ABCB11ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318507-A2 | Potassium Channel Activators for the Prevention and Treatment of Dystonia and Dystonia Like Symptoms | RUNDFELDT CHRIS | 2009-12-24 | — | — | US | claimed |
| US-20090137641-A1 | Potassium Channel Activators for the Prevention and Treatment of Dystonia and Dystonia-Like Symptoms | RUNDFELDT CHRIS | 2009-05-28 | — | — | US | claimed |
| EP-2012769-A1 | POTASSIUM CHANNEL ACTIVATORS FOR THE PREVENTION AND TREATMENT OF DYSTONIA AND DYSTONIA-LIKE SYMPTOMS | Rundfeldt, Chris (DE) | 2009-01-14 | — | — | EP | claimed |
| WO-2007128462-A1 | POTASSIUM CHANNEL ACTIVATORS FOR THE PREVENTION AND TREATMENT OF DYSTONIA AND DYSTONIA-LIKE SYMPTOMS | RUNDFELDT CHRIS (DE) | 2007-11-15 | — | — | WO | claimed |
| US-20150037318-A1 | TREATMENT OF MULTIPLE SCLEROSIS WITH COMBINATION OF LAQUINIMOD AND FLUPIRTINE | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2015-02-05 | — | — | US | disclosed |
| US-20140243350-A1 | USE OF SEROTONIN RECEPTOR AGONISTS FOR TREATMENT OF MOVEMENT DISORDERS | CONTERA PHARMA APS (DK) | 2014-08-28 | — | — | US | disclosed |
| US-20090318507-A2 | Potassium Channel Activators for the Prevention and Treatment of Dystonia and Dystonia Like Symptoms | RUNDFELDT CHRIS | 2009-12-24 | — | — | US | disclosed |
| US-20090137641-A1 | Potassium Channel Activators for the Prevention and Treatment of Dystonia and Dystonia-Like Symptoms | RUNDFELDT CHRIS | 2009-05-28 | — | — | US | disclosed |
| EP-2012769-A1 | POTASSIUM CHANNEL ACTIVATORS FOR THE PREVENTION AND TREATMENT OF DYSTONIA AND DYSTONIA-LIKE SYMPTOMS | Rundfeldt, Chris (DE) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007128462-A1 | POTASSIUM CHANNEL ACTIVATORS FOR THE PREVENTION AND TREATMENT OF DYSTONIA AND DYSTONIA-LIKE SYMPTOMS | RUNDFELDT CHRIS (DE) | 2007-11-15 | — | — | WO | disclosed |
| EP-0160865-A2 | 2-Amino-3-ethoxycarbonylamino-6-(p-fluoro-benzylamino)-pyridine-gluconate and pharmaceutical compounds containing this product | Degussa Aktiengesellschaft (DE) | 1985-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150037318-A1 | TREATMENT OF MULTIPLE SCLEROSIS WITH COMBINATION OF LAQUINIMOD AND FLUPIRTINE | HTR5A, LPAR5, MRGPRX1 | KCNQ3 127/4885KCNQ2 82/4885HSD17B10 3079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.